Compare EMBC & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EMBC | KIO |
|---|---|---|
| Founded | 1924 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.7M | 470.1M |
| IPO Year | 2021 | 2011 |
| Metric | EMBC | KIO |
|---|---|---|
| Price | $8.84 | $10.85 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $18.50 | N/A |
| AVG Volume (30 Days) | ★ 766.6K | 319.6K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | ★ 6.67% | N/A |
| EPS Growth | ★ 20.90 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.17 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.72 | $10.67 |
| 52 Week High | $15.55 | $12.83 |
| Indicator | EMBC | KIO |
|---|---|---|
| Relative Strength Index (RSI) | 36.01 | 35.04 |
| Support Level | $8.72 | N/A |
| Resistance Level | $9.47 | $12.51 |
| Average True Range (ATR) | 0.35 | 0.16 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 15.35 | 25.00 |
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.